Spasticity and Marijuana: Review and Meta-analysis

Cannabis and cannabinoid drugs are increasingly being used to treat a variety of diseases and alleviate symptoms, but their efficacy for specific indications is still unclear. A systematic review was conducted to investigate the benefits and adverse events (AEs) of cannabinoids.

Analyzing randomized clinical trials of cannabinoids for indications such as chronic pain, spasticity, depression, anxiety disorder, and more. While most trials showed an improvement in symptoms associated with cannabinoids, these associations did not reach statistical significance in all trials.

Cannabinoids were found to be associated with a greater reduction in pain and spasticity, as well as a reduction in nausea and vomiting due to chemotherapy. However, the use of cannabinoids was also associated with an increased risk of short-term AEs, including serious AEs. Common AEs included dizziness, dry mouth, nausea, and fatigue, among others.

The study concludes that there is moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity, and low-quality evidence suggests that cannabinoids may be helpful in treating nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.

While the results are promising, it is important to note the potential risks associated with the use of cannabinoids. As with any medication, it is crucial to work closely with a medical professional to determine the best course of treatment.